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Time for a ‘radical’ change to Active Surveillance for prostate cancer…? 
 
Jenny L Donovan and Freddie C Hamdy 
Over the past two decades, Active Surveillance (AS) has become an acceptable management option for 
men with low-risk clinically localised prostate cancer. A thorough literature review published in this 
month's issue of European Urology shows that a plethora of factors influence whether men choose to un-
dergo or stay on AS - ranging from individual patient characteristics such as age or cancer features, through 
family and social support, to attitudes communicated by clinicians and influences from healthcare organisa-
tions and policy directives.1 These findings chime with other reviews showing the lack of consensus over 
fundamental aspects of AS programmes such as inclusion criteria, monitoring strategies and 'triggers' for 
change of management.2 With such a diversity of approaches and influences, and recent transformational 
developments in the field, how should AS now be implemented? 
The development of AS  
The history of AS is relatively short and somewhat controversial. The concept was first discussed as a strat-
egy distinct from ‘watchful waiting’ in the late-1990s - ‘Active Surveillance’ in North America3 and ‘Active 
Monitoring - AM’ in the UK.4 It started because of the realisation that many of the localised prostate can-
cers identified by increasingly widespread PSA testing were low-risk and posed little threat to a man's 
length of life,5 yet most were being treated radically, with serious consequences for men’s sexual, urinary 
and bowel function. Increasing numbers of men are now undergoing AS successfully, underpinned by evi-
dence from a small number of well-characterised cohort studies (e.g.3,6) but little information about optimal 
services to support men.1  
Recent ‘game-changing’ developments 
Two recent developments should provide the impetus for a clearer consensus about AS. First, the ProtecT 
trial found no difference in prostate cancer mortality between active monitoring (AM), radiotherapy and 
surgery at a median of 10 years’ follow-up, but metastases were found in twice as many men in the AM 
group (6%) compared with surgery and radiotherapy (3%) - the first robust comparative evidence about 
outcomes of a surveillance approach.7,8  Second, the PRECISION trial demonstrated that pre-biopsy multi-
parametric MRI (mpMRI) with or without targeted biopsies was more effective at reducing the detection of 
low-risk prostate cancer and increasing the identification of clinically significant cancer than standard 10-
12-core ultrasound-guided biopsies.9 It is likely this will transform the diagnostic pathway.  
ProtecT AM was inclusive: men with clinically localized prostate cancer were eligible for inclusion - con-
trasting with AS programmes restricted to men with low or very low-risk prostate cancer. ProtecT AM com-
prised low intensity monitoring based on PSA kinetics, with any concerns raised by patient or clinician at 
  
any time leading to a review that could include re-evaluation of cancer status and then continuing on AM or 
changing to a radical option - contrasting with AS programmes with regular repeat-biopsy. After a median 
of two years, 20% allocated to ProtecT AM had changed to a radical option (50% at a median of 10-years)7 - 
a level of change consistent with AS programmes with repeat-biopsy.  
A misconception has arisen that the ProtecT trial cohort included mostly low or very low-risk prostate can-
cer because 75% had Gleason score 6 and 76% T1c tumours,10 but combining PSA, T-stage and Gleason 
score, only two-thirds had true low-risk cancer. ProtecT was under-staged: 29% who had surgery had stage 
pT3 disease; it can be assumed that a similar proportion with extra-capsular disease was in the AM group. 
ProtecT employed a 10-core TRUS-guided biopsy protocol (without mpMRI, which was then unavailable). 
Men undergoing ProtecT AM thus harboured considerably more higher stage and intermediate- and high-
risk cancer than was apparent from their diagnostic information. Yet their risk of death from prostate can-
cer over a median of 10 years was extremely low and some with intermediate-risk cancer did not progress 
on AM.  
Time for a ‘radical’ change to Active Surveillance …?  
The evidence presented above does not negate the AS approach for men with clinically localised prostate 
cancer. Far from it - cohort studies showing low risks of progression and death, the potential for more accu-
rate diagnosis with mpMRI according to PRECISION, increasing understanding of the genomics and biologi-
cal behaviour of prostate cancer, and the ProtecT results all confirm the importance and viability of AS/AM 
approaches. While the ProtecT AM protocol cannot be implemented because of the increased risk of me-
tastases, many of today's AS programmes are also inappropriate, particularly those restricted only to pa-
tients with very low-risk disease and including numerous repeat-biopsies with risks of infection and lack of 
targeting.  
There is thus a need for a ‘radical’ re-think about AS/AM in terms of patient inclusion, monitoring strate-
gies, and triggers for change to radical treatment that maintain men within the 'window of curability'. Using 
recent evidence, clinicians can have more confident and open discussions about management options with 
patients diagnosed with low- and intermediate-risk prostate cancer. Men do not need to rush to choose a 
treatment; there is time to consider their wishes and perspectives in relation to the evidence about the ef-
fectiveness and impact of each of the major options. Some men may wish to avoid the risk of metastases at 
all costs and opt for surgery or radiotherapy immediately or a strict AS protocol with frequent testing, in-
cluding repeat-biopsies. Others may be willing to accept a risk of progression if they are able to have less 
frequent and invasive monitoring that enables them to continue living their everyday lives.  
New protocols need to be developed to support men on AS/AM, and their families, over many years. Les-
sons can be learned from the management of chronic health conditions such as arthritis - developing stand-
ardized guidelines for clinicians and supportive information for patients – as suggested in this month's arti-
cle.1 
  
The time is right to review existing AS/AM programmes. We need to build a new evidence-based consensus 
to ensure that as many men as possible can avoid unnecessary treatment while those who do need it re-
ceive radical interventions. In addition, why not also consider reducing widespread PSA testing and imple-
ment more accurate diagnostic techniques to protect men from being diagnosed with low-risk prostate 
cancer in the first place? 
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